<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277653</url>
  </required_header>
  <id_info>
    <org_study_id>AFP-PIVKA</org_study_id>
    <nct_id>NCT01277653</nct_id>
  </id_info>
  <brief_title>Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma</brief_title>
  <official_title>Prospective, Randomized Study of PIVKA-II and AFP Measurement Every 3 Months Compared to AFP Every 6 Months in Surveillance Program for Early Detection of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role
      of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program
      for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if
      the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early
      stages of HCC than the 6 month interval of AFP that is commonly used
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role
      of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program
      for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if
      the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early
      stages of HCC than the 6 month interval of AFP that is commonly used
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>the difference of curative treatments &amp; survival rates</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference of early detection rates of HCC between both groups</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PIVKA-II and AFP 6 months</arm_group_label>
    <description>PIVKA-II and AFP measurement every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tumor maker interval every 6 month</arm_group_label>
    <description>tumor maker interval every 6 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tumor maker interval shortly</intervention_name>
    <description>tumor maker interval every 3 month</description>
    <arm_group_label>tumor maker interval every 6 month</arm_group_label>
    <other_name>tumor maker interval every 3 month</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Liver cirrhosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LC

        Exclusion Criteria:

          -  previous HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoung HA LEE, MD</last_name>
    <role>Study Director</role>
    <affiliation>OFF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myoung Ha Lee, MD</last_name>
      <phone>+82-10-2506-7592</phone>
      <email>leemyoungha@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>January 14, 2011</last_update_submitted>
  <last_update_submitted_qc>January 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Do Young Kim</name_title>
    <organization>Department of Internal Medicine, Yonsei University College of Medicine</organization>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

